A number of other research firms also recently issued reports on CYDY. Zacks Investment Research upgraded CytoDyn from a hold rating to a buy rating and set a $0.75 price target on the stock in a research note on Tuesday, September 18th. ValuEngine upgraded CytoDyn from a hold rating to a buy rating in a research note on Thursday, November 1st.
CYDY opened at $0.58 on Tuesday. CytoDyn has a one year low of $0.40 and a one year high of $0.84.
CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.
Read More: What is the Book Value of a Share?
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.